Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
LYMPHIR (denileukin diftitox-cxdl) is a recombinant fusion protein that combines the interleukin-2 (IL-2) receptor binding domain with diphtheria toxin fragments.
Lead Product(s): Denileukin Diftitox-cxdl
Therapeutic Area: Oncology Product Name: Lymphir
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Citius Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 29, 2023
Details:
As part of the license agreement, Exelixis will have the right to use the AJICAP technology to support its aim of advancing multiple Antibody-drug Conjugates with the potential for higher efficacy and lower toxicity than currently available options.
Lead Product(s): Antibody-drug Conjugate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Exelixis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 10, 2023